Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Chris Earwood"'
Autor:
Rami Owera, Howard A. Burris, Mathew John Joseph, Ruth E. Lamar, David R. Spigel, Johanna C. Bendell, Cassie M. Lane, D. S. Thompson, Chris Earwood, William Penley, Todd M. Bauer
Publikováno v:
Cancer Investigation. 34:265-270
AUY922 is an inhibitor of heat shock protein 90 (Hsp90). Hsp90 inhibitors induce kit degradation in preclinical gastrointestinal stromal tumor (GIST) models. This trial was designed to determine the progression-free survival (PFS) of patients with GI
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a09afdb1c50d9eff792e7466b133bfb
https://doi.org/10.1080/07357907.2016.1193746
https://doi.org/10.1080/07357907.2016.1193746
Autor:
Denise A. Yardley, Chris Earwood, Roger Inhorn, Patrick B. Murphy, David Drosick, Natalie R. Dickson, John D. Hainsworth
Publikováno v:
Clinical Breast Cancer. 16:180-187
Background The purposes of the present phase I/II trial were (1) to define tolerable doses of ixabepilone and sorafenib when used in combination and (2) to evaluate the efficacy and toxicity of this combination in the treatment of patients with human
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d5dd3c7961e864a4f4bd8779b5e8a63
https://doi.org/10.1016/j.clbc.2016.02.003
https://doi.org/10.1016/j.clbc.2016.02.003
Autor:
Patrick Murphy, Lowell L. Hart, Adil Moyhuddin, Jeffrey Patton, Dana S. Thompson, Suzanne F. Jones, Chris Earwood, Jeffrey R. Infante, Shubham Pant, Johanna C. Bendell, William Charles Penley, Cassie M. Lane
Publikováno v:
Cancer Investigation. 33:477-482
Background: This phase I study determined the maximum tolerated dose (MTD) of AUY922 with capecitabine in advanced solid tumors. Methods: Capecitabine 1000mg/m2 PO BID was administered with escalating doses of AUY922 IV; the MTD of AUY922 was combine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::522d00ebf1128ee0f4191dcdeae22ebd
https://doi.org/10.3109/07357907.2015.1069834
https://doi.org/10.3109/07357907.2015.1069834
Autor:
Denise Yardley, Karyn Dyehouse, Aruna Mani, Carmen Calfa, David Drosick, Kathleen Yost, Diana Shipley, Raven Quinn, Robyn Young, Lindsey Finney, Chris Earwood, Mythili Shastry, John Hainsworth
Publikováno v:
Cancer Research. 75:P3-11
Background: Pathologic complete response (pCR) following neoadjuvant chemotherapy for locally advanced breast cancer strongly correlates with improved disease-free survival, rates of breast-conserving surgery, and provides an early indicator of treat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::20fe0c133f9e1d7eec81946f44c9c984
https://doi.org/10.1158/1538-7445.sabcs14-p3-11-08
https://doi.org/10.1158/1538-7445.sabcs14-p3-11-08
Autor:
David Wenk, Andrew S. Kennedy, Brian Hemphill, Johanna C. Bendell, Chris Earwood, Cassie M. Lane, D. S. Thompson
Publikováno v:
Cancer investigation. 35(8)
Background: This phase II study combined aflibercept with preoperative chemoradiation for patients with stage II/III rectal cancer, followed by mFOLFOX6/aflibercept. Methods: Patients received preoperative 5-FU (days 1–43), radiation (weeks 1–6),
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::630f71256ca86ee2523db4e6495adb55
https://pubmed.ncbi.nlm.nih.gov/28792245
https://pubmed.ncbi.nlm.nih.gov/28792245
Autor:
Michel E. Kuzur, Dianna Shipley, Mathew John Joseph, Laura Blakely, Cassie M. Lane, Mark Mainwaring, Chris Earwood, Johanna C. Bendell, Chandra Reddy, Ronald Blachly, Kirk Barnes
Publikováno v:
Cancer investigation. 35(6)
This phase-2 trial evaluated the efficacy of axitinib as maintenance therapy for patients with metastatic colorectal cancer (mCRC) following first-line treatment with FOLFOX/bevacizumab. Patients with mCRC received mFOLFOX/bevacizumab followed by axi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::692c20fb281726eabcbbe4498488e614
https://pubmed.ncbi.nlm.nih.gov/28426267
https://pubmed.ncbi.nlm.nih.gov/28426267
Autor:
J. H. Barton, David R. Spigel, Chris Earwood, Johanna C. Bendell, Lowell L. Hart, Cassie M. Lane, Howard A. Burris, Suzanne F. Jones, Jeffrey R. Infante
Publikováno v:
Investigational New Drugs. 33:187-193
To determine the maximum tolerated dose (MTD) of the combination of linsitinib (OSI-906), a dual inhibitor of IGFR and IR tyrosine kinase activity, and everolimus as treatment for patients with refractory metastatic colorectal cancer (mCRC). Eligible
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3606b88aa816d856b6c6a4d17473f3e
https://doi.org/10.1007/s10637-014-0177-3
https://doi.org/10.1007/s10637-014-0177-3
Autor:
Douglas Flora, Peter Ruehlman, David M. Waterhouse, Cassie M. Lane, Michael McCleod, Kent C. Shih, Evan Z. Lang, Kathryn B. Alguire, Johanna C. Bendell, N. W. Peacock, Chris Earwood, Ahmed Zakari
Publikováno v:
Cancer investigation. 34(5)
Purpose: To evaluate efficacy and safety of bevacizumab, pertuzumab, and octreotide depot for advanced neuroendocrine tumors.Methods: Patients received bevacizumab 15 mg/kg and pertuzumab 420 mg IV q21 days with octreotide depot 30 mg IM q28 days.Res
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a665dd3a694b22d47ead3f6e5e249420
https://pubmed.ncbi.nlm.nih.gov/27127841
https://pubmed.ncbi.nlm.nih.gov/27127841
Autor:
Victor G. Gian, Mark Moskowitz, Ahmed Zakari, Chris Earwood, Ralph V. Boccia, Richard LoCicero, David M. Waterhouse, Andrew Lipman, Johanna C. Bendell, A. A. Meluch, Cassie M. Lane, James D. Peyton
Publikováno v:
The Oncologist
Lessons Learned This regimen is a viable option for patients with liver-only metastatic colorectal cancer. Enrollment criteria for future studies should include testing for the newly identified KRAS mutations. Background. Patients with liver-only met
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5dd8bb578a8d2abed1e310c9625b1b15
https://pubmed.ncbi.nlm.nih.gov/26911408
https://pubmed.ncbi.nlm.nih.gov/26911408
Publikováno v:
Cancer investigation. 33(3)
Purpose: To investigate the combination of liposomal doxorubicin/pazopanib in advanced relapsed/refractory ovarian cancer. Patients and Methods: Twenty-two patients received liposomal doxorubicin/pazopanib. Initial doses (liposomal doxorubicin, 40 mg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e7fd1ada2a78976b161ca5e7a7d9531
https://pubmed.ncbi.nlm.nih.gov/25615852
https://pubmed.ncbi.nlm.nih.gov/25615852